Abstract P4-22-18: phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer
Authors
Munster, PIsmail-Khan, R
Garcia-Estevez, L
Mayer, I
Becerra, C
Hamilton, E
De Boer, R
Wardley, Andrew M
Im, S
Teixeira, L
Wang, Y
Su, F
Germa, C
Hirawat, S
Juric, D
Affiliation
University of California San Francisco, San Francisco, CA;Issue Date
2017-02-14
Metadata
Show full item recordCitation
Abstract P4-22-18: phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer 2017, 77 (4 Supplement):P4-22-18 Cancer ResearchJournal
Cancer ResearchDOI
10.1158/1538-7445.SABCS16-P4-22-18Type
Meetings and ProceedingsLanguage
enISSN
0008-54721538-7445
ae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.SABCS16-P4-22-18